| Summary: | Pulsed corticosteroid is highly effective in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with the advantage of a higher potential in achieving therapy-free remission in comparison to immunoglobulin. More recently, fixed pulsed corticosteroid regime have been demonstrated to have better efficacy with fewer side effects than daily dosing. However, distinct gaps exist in current treatment guidelines on what is the best corticosteroid regimen. We illustrate a novel treatment perspective with an individualised pulsed oral dexamethasone dosing modifying method in 2 treatment-naïve patients with typical CIDP based on clinical response and side effect profiles. Both patients achieved remission on assessment with clinically validated CIDP disability and impairment scales. Dose reduction as early as the third month did not lead to clinical deterioration. The similarities between both patients were young females with no co-morbidities, early disease presentation, mild sensorimotor impairment, and functional disability at presentation and less aggressive disease progression. Therefore, in a selected group of CIDP patients, a lower cumulated corticosteroid dose may be sufficient to achieve clinical remission with individualized dosing modification. To the best of our knowledge, this innovative corticosteroid treatment insight for CIDP has not been described in the literature.
|
|---|
